Translate page

CML publications

Please find below a selection of interesting articles on CML from peer-reviewed journals. Recent publications include:

Clinical papers

Scientific papers

More CML Publications 2023

Clinical Publications Scientific Publications
May 2023
Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplant - Review
Uhm J. Blood Res, April 2023
- open access publication
Frequency and driver mutation diversity in concomitant chronic myeloid leukemia and Philadelphia chromosome-negative myeloproliferative neoplasm
Langabeer SE et al. Int J Hematol, April 2023 (epub ahead of print)
Developing therapeutic approaches for CML: a review
Kumar V et al. Mol Cell Biochem, May 2023
Differentiation of imatinib-resistant chronic myeloid leukemia cells with BCR-ABL-T315I mutation induced by Jiyuan Oridonin A.
Xu Y et al. Cancer, May 2023
– open access publication
The EMA assessment of Asciminib for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who were previously treated with at least two tyrosine kinase inhibitors
Tesileanu CMS et al. Oncologist, May 2023 (epub ahead of print)
– open access publication
I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition
Gao C et al. Front Pharmacol, April 2023
– open access publication
Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase focusing on age and dose effects
Tokuhira M et al. Int J Hematol, May 2023
(epub ahead of print)

Inhibition of casein kinase 2 induces cell death in tyrosine kinase inhibitor resistant chronic myelogenous leukemia cells
Mitrovsky O et al. PLoSOne, May 2023
– open access publication

 
Impact of obesity surgery on tyrosine kinase inhibitor responses and survival outcomes in patients with chronic myeloid leukemia: Further data are still warranted!
Eskazan AE et al. Cancer, May 2023
(epub ahead of print)
 
JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response
Tossoni L et al. Ann Hematol, May 2023
 
April 2023
The outcome of post-transplant asciminib in patients with CML
Fernando F et al. Bone Marrow Transplant, April 2023 (epub ahead of print)
New patterns of genetic instability in chronic myelogenous leukemia: interesting, but not ready for clinical use
Schiffer CA. Haematologica, April 2023
(epub ahead of print)
– open access publion
Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial
Réa D et al. Leukemia, April 2023 (epub ahead of print)
– open access publication
The structure of the hematopoietic system can explain chronic myeloid leukemia progression
Pérez-Jiménez M et al. Sci Rep, April 2023
– open access publication
Management of chronic myeloid leukemia in 2023 – Common ground and common sense - Review
Senapati J et al. Blood Cancer J, April 2023
– open access publication
Characterization of bone marrow niche in chronic myeloid leukemia patients identifies CXCL14 as a new therapeutic option
Polinska M et al. Blood, April 2023
(epub ahead of print)
Efficacy and safety of nilotinib in chronic myeloid leukemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study
Dulucq S et al. Br J Haematol, April 2023
(epub ahead of print)
– open access publication
IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia
Fiordi B et al. Haematologica, April 2023
(epub ahead of print)
– open access publication
Clonal hematopoiesis onset in chronic myeloid leukemia patients developing an adverse cardiovascular event
Tarantini F et al. Leuk Res, April 2023
Molecular subtypes predict therapeutic responses and identifying and validating diagnostic signatures based on machine learning in chronic myeloid leukemia
Zhong FM et al. Cancer Cell Int, April 2023
open access publication
Managing women of childbearing age with chronic myeloid leukemia: Safety and treatment considerations
Expert Rev Hematol, April 2023
(epub ahead of print)
Molecular subtypes predict therapeutic responses and identifying and validating diagnostic signatures based on machine learning in chronic myeloid leukemia
Zhong FM et al. Cancer Cell Int, April 2023
– open access publication 
An analysis of dasatinib treatment patterns in patients with chronic myeloid leukemia after experiencing pleural effusion during dasatinib therapy
McBride A et al. Acta Haematol, April 2023
(epub ahead of print)  
 
Efficacy and safety of nilotinib as frontline therapy in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials
Luciano L et al. Ann Hematol, April 2023
(epub ahead of print)
– open access publication
 
Applications of machine learning in chronic myeloid leukemia - Review
Elhadary M et al. Diagnostics(Basel),
April 2023 – open access publication
 
Breaking the mold: asciminib as a standard of care of the therapeutic armamentarium of chronic myeloid leukemia in the upfront setting
Yilmaz R et al. Future Oncol, April 2023 (epub ahead of print)

 

Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia – Review
Han JJ et al. Blood Res, April 2023
(epub ahead of print)
– open access publication
 
Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings - Review
Cheng F et al. Front Oncol, April 2023
– open access publication
 
Assessment of imatinib as a primary treatment of chronic myeloid leukemia in chronic phase: a Cohort Study
Merin D et al. J Oncol Pharm Pract,
April 2023
 
March 2023
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL
Hochhaus A et al. Leukemia, March 2023
– open access publication
AMPK inhibition induces MCL1 mRNA destabilization via the p38 MAPK/miR-22/HuR axis in chronic myeloid leukemia cells
Lee YC et al. Biochem Pharmacol,
March 2023
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results
Mauro MJ et al. Leukemia, March 2023
(epub ahead of print) – open access publication
The interplay between telomeric complex members and BCR::ABL1 oncogenic tyrosine kinase in the maintenance of telomere lengths in chronic myeloid leukemia
Deregowska A et al. J Cancer Res Clin Oncol, March 2023 (epub ahead of print) – open access publication
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention
Shanmunagathan N et al. Haematologica, March 2023 (epub ahead of print) – open access publication 
Induction of DNMT1-dependent demethylation of SHP-1 by the natural flavonoid compound Baicalein overcame imatinib-resistance in CML CD34+ cells
Xu X et al. Cell Commun Signal,
March 2023 – open access publication
Editorial: Advances in the treatment of chronic myeloid leukemia
Eskazan AE et al. Front Oncol, March 2023
– open access publication
Imatinib blocks tyrosine phosphorylation of Smad4 and restores TFG-ß growth-suppressive signaling in BCR-ABL1-positive leukemia
Wang L et al. Signal Transduct Target Ther, March 2023 – open access publication
High-risk additional cytogenetic aberrations in a Dutch chronic phase chronic myeloid leukemia patient population
Kockerols CCB et al. Haematologica, March 2023 (epub ahead of print) – open access publication 
The prognostic and therapeutic potential of HO-1 in leukemia and MDS – Review
Sadeghi M et al. Cell Commun Signal, March 2023 – open access publication
Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence
Shallis RM et al. Blood Adv, March 2023
(epub ahead of print) – open access publication
NOX2 and NOX4 control mitochondrial function in chronic myeloid leukemia
Romo-González M et al. Free Radic Biol Med, March 2023
– open access publication 
The economic burden of chronic myeloid leukemia in patients with later lines: Findings from a real-world analysis in Italy
Breccia M et al. Adv Ther, March 2023
– open access publication
TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN
Qiu Q et al. Signal Transduct Target Ther, March 2023 – open access publication 
A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia
Krishnan V et al. Blood, March 2023 (epub ahead of print)
Molecular mechanisms of tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Kaehler M and Cascorti I. Handb Exp Pharmacol,
March 2023 (epub ahead of print) 
Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian Medicines Agency (AIFA)
Breccia M et al. Ann Hematol, March 2023
(epub ahead of print)
 
Current CML guidelines overemphasize second generation TKIs: revisiting the paradigm
Walia A and Prasad V. Blood Cancer J, March 2023 – open access publication
 
Eltrombopag for tyrosine kinase inhibitors-associated thrombocytopenia in chronic myeloid leukemia
Aleem A et al. Int J Hematol, March 2023
(epub ahead of print)
 
Association between bariatric surgery and outcomes in chronic myeloid leukemia
Haddad FG et al. Cancer, March 2023
(epub ahead of print) 
 
Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase – Review
Choi EJ. Blood Res, March 2023
(epub ahead of print)
– open access publication 
 
Patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia (RODEO study): study protocol for prospective, multicentre, single-arm trial
Djodikromo MF et a. BMC Cancer,
March 2023 – open access publication 

 

February 2023
 

Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells
Tsubaki M et al. BMB Rep, February 2023
– open access publication

Tyrosine kinase inhibitors combined with venetoclax and azacytidine as an effective therapy for the novo lymphoid blast phase-chronic myeloid leukemia
Yang Z et al. Leuk Res, February 2023
(epub ahead of print)
Repurposing the Bis-Biguanide Alexidine in combination with tyrosine kinase inhibitors to eliminate leukemic stem/progenitor cells in chronic myeloid leukemia
Muselli F et al. Cancers(Basel), February 2023 – open access publication
Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: characteristics, potential mechanism, and clinical management strategies – Review
Cheng F et al. Front Oncol, February 2023
– open access publication

Discovery of CZS-241: A potent, selective, and orally available Polo-like kinase 4 inhibitor for the treatment of CML
Sun Y et al. J Med Chem, February 2023

 
Cardiovascular toxicities associated with tyrosine kinase inhibitors - Review
Sahegh N et al. Curr Cardiol Rep, February 2023 (epub ahead of print)
Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia
Jiang B et al. Front Oncol, February 2023
– open access publication
The bone marrow immune environment in CML: Treatment responses, treatment-free remission and therapeutic vulnerabilities
Patterson SD & Copland M. Curr Hematol Malig Rep, February 2023 (epub ahead of print)
– open access publication
A survey of patient experience in CML: American and Canadian Perspectives
Hillis C et al. Patient Prefer Adherence, February 2023
– open access publication
 
Importance of tyrosine kinase inhibitor treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-Free study
Yoshida C et al. Int J Hematol, February 2023
(epub ahead of print) – open access publication
 
Five-year cardiovascular outcomes in patients with chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib: A cohort study using data from a large multinational collaborative network
Nunes RAB et al. Front Cardiovasc Med, February 2023 – open access publication 
 
Cognition in patients treated with targeted therapy for chronic myeloid leukemia: a controlled comparison
Hyland KA et al. Leuk Lymphoma, February 2023
 
Family planning and pregnancy in patients with chronic myeloid leukemia – Review
Berman E et al. Curr Hematol Malig Rep, February 2023 (epub ahead of print)
 
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modelling and pathway analysis
Radich JP et al. Haematologica, February 2023
(epub ahead of print) – open access publication
 
January 2023
Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in CML
Irani YD et al. Blood Adv, January 2023
(epub ahead of print)
– open access publication 
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL
Hochhaus A et a. Leukemia, January 2023
(epub ahead of print)
– open access publication
RHOA-regulated IGFBP2 promotes invasion and drives progression of BCR-ABL1 chronic myeloid leukemia
Zhang H et al. Haematologica, January 2023
– open access publication
Matching adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
Atallah E et al. J Caner Res Clin Oncol, January 2023 (epub ahead of print) – open access publication
Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib
Häselbarth L et al. Cancer Immunol Immunother, January 2023 (epub ahead of print)
– open access publication 
Allogeneic transplantation for chronic myeloid leukemia: I’m not dead yet!
Radich J. Am J Hematol, January 2023
– open access publication
mTORC2 is activated under hypoxia and could support chronic myeloid leukemia stem cells
Panuzzo C et al. Int J Mol Sci, January 2023
– open access publication 
Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor
Bidikian A et al. Am J Hematol (epub ahead of print)
BH3 mimetics and TKI combined therapy for CML
Brumatti G et al. Biochem, January 2023
– open access publication 
The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors
Jabbour EJ et al. Am J Hematol, January 2023 (epub ahead of print)
Differential inhibition of T cell receptor and STAT5 signalling pathways determine the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia
Harrington P et al. Haematologica, January 2023
(epub ahead of print)
– open access publication
A systematic review on second treatment-free remission (TFR) attempt in chronic myeloid leukemia (CML): Can it be applied in clinical practice? - Review
Çiftçiler R et al. Clin Lymphoma Myeloma Leuk (epub ahead of print)
  Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic-phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring
Bataller A et al. Leuk Lymphoma, January 2023 (epub ahead of print)
  Is it time to reconsider molecular response milestones in CML?
Walia A and Prasad V. Am J Hematol, January 2023 (epub ahead of print)

Find publications on pediatric CML here
Find publications on COVID-19 and CML here
Find CML publications from the emerging regions here

CML Publications 2014-2022

Access 2022 CML publications here

Access 2021 CML publications here

Access 2020 CML publications here

Access 2019 CML publications here

Access 2018 CML publications here

Access 2017 CML publications here

Access 2016 CML publications here

Access 2015 CML publications here

Access 2014 CML publications here


Would you like to suggest an interesting paper or article? >> Please provide us with the details here and we will be happy to review your suggestion!

Search for more publications on CML at PubMed.gov